Naurex is a biopharmaceutical company developing novel modulators of the NMDA receptor to treat challenging diseases of the brain and central nervous system.
Our lead product candidate, rapastinel (GLYX-13), is in late-stage clinical development as an adjunctive therapy for patients with major depressive disorder who are unable to achieve an adequate response to their current anti-depressants. Rapastinel has shown rapid, substantial, and sustained antidepressant activity in Phase 2 clinical studies and has been well-tolerated, with none of the psychosis-like side effects that limit other drugs targeting NMDA receptors. Our second-generation compound, NRX-1074, is an orally active agent in Phase 2 clinical development as a monotherapy for the treatment of major depressive disorder.
In July 2015, Naurex Inc. entered into a definitive agreement to be acquired by Allergan plc. The transaction was successfully closed in August 2015. For more information, please visit www.naurex.com or www.allergan.com.
Our lead product candidate, rapastinel (GLYX-13), is in late-stage clinical development as an adjunctive therapy for patients with major depressive disorder who are unable to achieve an adequate response to their current anti-depressants. Rapastinel has shown rapid, substantial, and sustained antidepressant activity in Phase 2 clinical studies and has been well-tolerated, with none of the psychosis-like side effects that limit other drugs targeting NMDA receptors. Our second-generation compound, NRX-1074, is an orally active agent in Phase 2 clinical development as a monotherapy for the treatment of major depressive disorder.
In July 2015, Naurex Inc. entered into a definitive agreement to be acquired by Allergan plc. The transaction was successfully closed in August 2015. For more information, please visit www.naurex.com or www.allergan.com.
Location: United States, Illinois, Evanston
Employees: 11-50
Total raised: $80M
Founded date: 2006
Investors 2
| Date | Name | Website |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | Genesys Ca... | genesyscap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.12.2014 | Series C | $80M | - |
Mentions in press and media 14
| Date | Title | Description |
| 27.07.2015 | Following Its $560M Acquisition, NU Drug Startup Naurex Launches New Research Company | This weekend Naurex, an Evanston-based biopharma company that creates depression-treating drugs, was acquired by Dublin-based pharmaceutical company Allergan for $560 million, plus success-based and sales-threshold milestone payments. Aller... |
| 28.01.2015 | 2014: A bumper year for the Midwest life sciences startups | Health IT: $562 million This data aggregation came from the BioEnterprise Midwest Healthcare Growth Capital Report. Ohio companies attracted the most capital – $499 million – with Minnesota a close second at $406 million. This is thanks, of... |
| 03.12.2014 | Naurex Raises $80M in Series C | EVANSTON, Ill, Biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), has completed an $80 million Series C financing round. >> Click here for more funding ... |
| 03.12.2014 | NU Biopharma Startup Naurex Raises $80M to Develop Drugs to Battle Depression | Naurex, a biopharmaceutical company born out of Northwestern that creates drugs to fight against diseases of the central nervous system, announced Wednesday that it has raised an $80 million Series C round. Launched in 2008, Naruex's latest... |
| 03.12.2014 | Northwestern spinout Naurex raises $80M Series C to bring antidepressant to Phase III | The Chicago-area company says that in clinical proof-of-concept studies, GLYX-13 “was well-tolerated and demonstrated rapid, robust and sustained antidepressant effects.” The drug works by targeting NMDA receptors, which increase synaptic p... |
| 06.05.2014 | Naurex picks up $25M to get its depression drugs through PhII | Evanston, IL's Naurex nailed down another $25 million in venture funding to accelerate its two-pronged depression program, posting positive midstage results for its top prospect. The latest funding comes entirely from existing shareholders,... |
| 17.12.2012 | Baxter joins Big Pharma funds on $38M B round for Naurex anti-depression R&D | Baxter's new venture fund has stepped up to take the lead on a $38 million B round for Naurex, an Evanston, IL-based biotech prepping for a Phase IIb study of its lead anti-depressant, which has already attracted the support of three big co... |
| 17.12.2012 | Naurex Raises $38M in Series B Financing | Naurex Inc., an Evanston, Illinois-based clinical-stage company focused on psychiatry and neurology, has raised $38m in Series B financing. The round was led by new investor Baxter Ventures, with participation from new investor Savitr Capit... |
| 17.12.2012 | VCs, corporate pharma investors put $38M behind Naurex’s new treatments for depression | Naurex is developing what it says is a new mechanism of action for modulating the NMDA receptor, which if overstimulated is thought to cause cell death associated with many neurological disorders. GLYX-13 is an IV drug that in initial clini... |
| 17.12.2012 | Naurex Completes $38M Series B | EVANSTON, IL, Clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, announced the completion of a $38 million Series B financing led by new investor Baxter Ventures. >> Click he... |
Show more